Aug 6, 2026 07:30AM
Jun 30, 2026 07:31AM
Jun 30, 2026 07:30AM
May 6, 2026 08:26AM
May 6, 2026 08:25AM
May 4, 2026 07:31AM
May 4, 2026 07:30AM InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
May 1, 2026 07:30AM
Apr 9, 2026 07:30AM
Mar 30, 2026 07:30AM
Mar 30, 2026 07:30AM
Mar 20, 2026 04:14PM
Mar 20, 2026 06:59AM
Mar 19, 2026 07:30AM InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
Jan 8, 2026 08:11AM
Jan 8, 2026 08:00AM
Dec 31, 2025 06:37AM
Dec 30, 2025 07:30AM
Dec 30, 2025 07:30AM
Dec 11, 2025 07:32AM
Dec 11, 2025 07:30AM InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
Nov 10, 2025 07:30AM
Nov 10, 2025 07:30AM
Sep 2, 2025 06:19AM
Aug 7, 2025 07:30AM
May 28, 2025 04:55AM
May 28, 2025 01:30AM
May 7, 2025 07:30AM InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 29, 2025 06:32AM
Mar 20, 2025 07:30AM
Mar 7, 2025 08:00AM
Feb 28, 2025 09:00AM
Jan 16, 2025 06:54AM
Jan 15, 2025 12:30PM
Jan 15, 2025 12:30PM InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
Nov 15, 2024 07:52AM
Nov 15, 2024 07:51AM
Nov 8, 2024 07:30AM
Sep 26, 2024 06:44AM
Sep 25, 2024 07:31AM
Sep 25, 2024 07:30AM
Aug 8, 2024 07:30AM InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 30, 2024 07:30AM
Jun 24, 2024 08:04AM
Jun 24, 2024 08:02AM
Jun 5, 2024 12:00PM
Jun 5, 2024 12:00PM
May 21, 2024 02:30PM
May 21, 2024 02:30PM InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
May 8, 2024 07:30AM

328,347 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All